Published in Cancer Weekly, February 12th, 2002
After 4 years of isolation, purification and in vitro testing, studies demonstrated direct antitumor activity in a wide range of cancers with 25-75% of cancerous cell growth inhibited, eliminated or both. Initial animal testing and toxicity studies demonstrated minimal toxicity and elimination of melanoma tumors in greater than 60% of test animals.
Isolation and testing of LP-9 for Credere was conducted at M.D. Anderson Cancer Center in Houston, Texas. ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.